Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health and Clearside Biomedical announced that the FDA has accepted the resubmitted New Drug Application for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension). The PDUFA action date is set for October 30, 2021. XIPERE targets macular edema associated with uveitis, a leading cause of vision loss. If approved, it would be the first therapy utilizing the suprachoroidal space for treatment. Clearside's SCS Microinjector aims to improve drug delivery, potentially minimizing adverse effects compared to traditional methods.
Bausch + Lomb and Prevent Blindness have initiated a collaboration for Cataract Awareness Month in June to educate the public about cataracts, a common cause of vision loss. They aim to alleviate anxiety surrounding cataract surgery, which has a 99% success rate. Bausch + Lomb will donate $1 for every social media 'like' or 'share' of certain posts, up to $50,000, to support Prevent Blindness's initiatives for increasing access to cataract care as cases are predicted to rise significantly.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will reduce its debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations. The redemption, set for June 30, 2021, will involve 6.125% Senior Notes due 2025, totaling $500 million redeemed this year. The company aims to improve its financial stability and decrease interest expenses. Forward-looking statements in the release caution investors about risks, including potential impacts from the ongoing COVID-19 pandemic.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced participation in the Jefferies Healthcare Conference on June 2, 2021, at 11:00 a.m. ET. CEO Joseph C. Papa, senior VP Sam Eldessouky, and senior VP Arthur J. Shannon will represent the company. A live webcast and audio archive will be available on Bausch Health’s Investor Relations page. The company focuses on improving lives through its healthcare products across eye health, gastroenterology, and dermatology sectors.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the pricing of its $1.6 billion offering of 4.875% senior secured notes due 2028. The proceeds will fund a Tender Offer to purchase outstanding 7.00% Senior Secured Notes due 2024 and related expenses. The notes are secured by company assets and guaranteed by its subsidiaries. The offering is subject to closing conditions and won't be registered under the Securities Act. This release highlights the company's strategy to manage debt and enhance liquidity.
Bausch Health Companies Inc. (BHC) announced a cash tender offer to purchase any outstanding 7.00% Senior Secured Notes due 2024. The total principal amount outstanding is $1.6 billion. The tender offer consideration is set at $989.25 per $1,000 principal amount, with an early tender premium of $30. The offer will expire on June 21, 2021, and holders must submit their tenders before the withdrawal deadline on June 7, 2021. If any notes remain outstanding post-offer, Bausch plans to redeem them on June 23, 2021. The offer is subject to the completion of a concurrent private offering of $1.6 billion in senior secured notes.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a $1.6 billion offering of new senior secured notes due 2028. The funds will be used to repurchase existing 7.00% senior secured notes due 2024 and cover related expenses. The notes will be guaranteed by the company’s subsidiaries and secured by assets. The offering targets qualified institutional buyers in the U.S. and non-U.S. persons under Regulation S. Additionally, the company plans to issue a conditional notice of redemption for the remaining 2024 Notes following the tender offer. The completion of the transactions is anticipated in Q2 2021, subject to market conditions.
Bausch Health announced that its gastroenterology business, Salix Pharmaceuticals, will present new data for TRULANCE®, XIFAXAN®, and PLENVU® at the Digestive Disease Week® (DDW) 2021 from May 21-23. Notably, a poster on TRULANCE® has been honored as a Poster of Distinction, awarded to only 10% of the accepted posters. The event emphasizes Salix's commitment to providing healthcare professionals with significant data on their medications to support treatment decisions.
Bausch + Lomb announced the results from the National Eye Institute's 10-Year Follow-on Study of the Age-Related Eye Disease Study 2 (AREDS2), reinforcing the effectiveness of its vitamin formula against moderate to advanced Age-Related Macular Degeneration (AMD). The NEI continues to endorse the PreserVision® AREDS 2 Formula, which contains 80mg of zinc and beneficial amounts of lutein and zeaxanthin. The findings support the importance of this specific nutrient mix for AMD patients, showcasing Bausch + Lomb's commitment to eye health and validated by over 3,800 participants over a decade.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in several investor conferences. Key executives, including CEO Joseph C. Papa, will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2021, at 11:00 a.m. ET. Other conferences include the Goldman Sachs Leveraged Finance Conference on May 17, 2021, at 1:10 p.m. ET, and the Barclays High Yield Bond and Syndicated Loan Conference on May 25, 2021, at 12:45 p.m. ET. Live webcasts will be available on their Investor Relations page.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
